Welcome!

News Feed Item

NAS911 Being Evaluated as Co-Therapeutic for Treatment of Influenza

SCOTTSDALE, AZ -- (Marketwired) -- 08/06/14 -- New Amsterdam Sciences (NAS), an emerging bioscience company focused on treating respiratory illnesses, announced today the completion of initial confirmatory studies in animal models designating Oseltamivir (Tamiflu) and NAS' lead compound NAS911 as a co-therapeutic for existing influenza antivirals currently available to flu patients. Tamiflu is presently the gold standard for prevention or inhibition of the spread of influenza virus A and B.

Studies were conducted through the Therapeutics Development Services program of the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). The goal of the research is to identify and advance the development of a co-therapeutic for existing antivirals for influenza. To date, New Amsterdam Sciences has explored the use of NAS911F in a multitude of different preclinical FDA accepted influenza infection models. Studies conducted by the company through third party facilities has demonstrated that NAS911F is shown to be a more effective treatment candidate than Tamiflu in side-by-side animal model comparison studies with end points of duration of flu, symptoms and other key factors supporting the work. An upcoming planned study for NAS is a co-therapeutic study combining Roche's TamiFlu with NAS's NAS911F with expectations of data demonstrating greater efficacy of TamiFlu combined with NAS911F as a combinatory influenza treatment. "Having the development interest and support from DMID for our flu candidate is extremely promising for our prospect pharma partnerships," said Michael Wilhelm, Director of Strategic Partnering. "This aids in the advancement of the most effective flu treatments currently available or in development." NAS is confident the co-therapeutic candidate will not only be more effective at the first symptom of flu but on severe and late stage flu cases as well. The company has explored seasonal and pandemic strains, observing reductions of morbidity and mortality in all models tested. NAS is currently exploring testing with additional influenza strains, including H7N9. These studies would to further explore the ideal dosing regimen for a clinical trial, as well as defining the mechanism of action of NAS911F in these models. NAS911F is a host-targeted immunomodulatory with a significant breadth and depth of safety and efficacy in the dozens of models tested to date.

"Working with the NIH's Influenza Therapeutics Development Program is a serious boon to the development of New Amsterdam Sciences' novel influenza therapeutic, NAS911F," said Jerry Toepfer, Vice President of NAS. "We anticipate this relationship will be an enormous leverage of time and money for our research, directly leading to our clinical trial objectives."

About the National Institute of Allergy and Infectious Diseases (NIAID)

NIAID conducts and supports research -- at NIH, throughout the United States, and worldwide -- to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About New Amsterdam Sciences

New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. The company's lead compound is NAS911, which is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, radiation sickness, and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial and government markets, focusing specifically on mass casualty biodefense applications. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, BARDA, NIH and more. For additional information, please visit www.newamsterdamsciences.com.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2652208

CORPORATE CONTACT:
Investor and Corporate Relations
Michael K. Wilhelm
480-477-7735
Email Contact
Email Contact

MEDIA CONTACT:
Dan Spelling
310-838-4010
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
Coca-Cola’s Google powered digital signage system lays the groundwork for a more valuable connection between Coke and its customers. Digital signs pair software with high-resolution displays so that a message can be changed instantly based on what the operator wants to communicate or sell. In their Day 3 Keynote at 21st Cloud Expo, Greg Chambers, Global Group Director, Digital Innovation, Coca-Cola, and Vidya Nagarajan, a Senior Product Manager at Google, discussed how from store operations and ...
In his session at 21st Cloud Expo, Carl J. Levine, Senior Technical Evangelist for NS1, will objectively discuss how DNS is used to solve Digital Transformation challenges in large SaaS applications, CDNs, AdTech platforms, and other demanding use cases. Carl J. Levine is the Senior Technical Evangelist for NS1. A veteran of the Internet Infrastructure space, he has over a decade of experience with startups, networking protocols and Internet infrastructure, combined with the unique ability to it...
"Infoblox does DNS, DHCP and IP address management for not only enterprise networks but cloud networks as well. Customers are looking for a single platform that can extend not only in their private enterprise environment but private cloud, public cloud, tracking all the IP space and everything that is going on in that environment," explained Steve Salo, Principal Systems Engineer at Infoblox, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventio...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
In his session at 21st Cloud Expo, James Henry, Co-CEO/CTO of Calgary Scientific Inc., introduced you to the challenges, solutions and benefits of training AI systems to solve visual problems with an emphasis on improving AIs with continuous training in the field. He explored applications in several industries and discussed technologies that allow the deployment of advanced visualization solutions to the cloud.
Gemini is Yahoo’s native and search advertising platform. To ensure the quality of a complex distributed system that spans multiple products and components and across various desktop websites and mobile app and web experiences – both Yahoo owned and operated and third-party syndication (supply), with complex interaction with more than a billion users and numerous advertisers globally (demand) – it becomes imperative to automate a set of end-to-end tests 24x7 to detect bugs and regression. In th...
"NetApp is known as a data management leader but we do a lot more than just data management on-prem with the data centers of our customers. We're also big in the hybrid cloud," explained Wes Talbert, Principal Architect at NetApp, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"Space Monkey by Vivent Smart Home is a product that is a distributed cloud-based edge storage network. Vivent Smart Home, our parent company, is a smart home provider that places a lot of hard drives across homes in North America," explained JT Olds, Director of Engineering, and Brandon Crowfeather, Product Manager, at Vivint Smart Home, in this SYS-CON.tv interview at @ThingsExpo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
"We work around really protecting the confidentiality of information, and by doing so we've developed implementations of encryption through a patented process that is known as superencipherment," explained Richard Blech, CEO of Secure Channels Inc., in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
High-velocity engineering teams are applying not only continuous delivery processes, but also lessons in experimentation from established leaders like Amazon, Netflix, and Facebook. These companies have made experimentation a foundation for their release processes, allowing them to try out major feature releases and redesigns within smaller groups before making them broadly available. In his session at 21st Cloud Expo, Brian Lucas, Senior Staff Engineer at Optimizely, discussed how by using ne...
Agile has finally jumped the technology shark, expanding outside the software world. Enterprises are now increasingly adopting Agile practices across their organizations in order to successfully navigate the disruptive waters that threaten to drown them. In our quest for establishing change as a core competency in our organizations, this business-centric notion of Agile is an essential component of Agile Digital Transformation. In the years since the publication of the Agile Manifesto, the conn...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"Cloud Academy is an enterprise training platform for the cloud, specifically public clouds. We offer guided learning experiences on AWS, Azure, Google Cloud and all the surrounding methodologies and technologies that you need to know and your teams need to know in order to leverage the full benefits of the cloud," explained Alex Brower, VP of Marketing at Cloud Academy, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clar...